Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/improving-bp-control-with-combined-renin-angiotensin-system-blockade-ZRk0N9kntP
References (69)
-
E. Okonofua, K. Simpson, Ammar Jesri, S. Rehman, V. Durkalski, B. Egan (2006)
Therapeutic Inertia Is an Impediment to Achieving the Healthy People 2010 Blood Pressure Control GoalsHypertension, 47
-
P. Verdecchia, G. Reboldi, F. Angeli, C. Borgioni, R. Gattobigio, L. Filippucci, Silvia Norgiolini, C. Bracco, C. Porcellati (2004)
Adverse Prognostic Significance of New Diabetes in Treated Hypertensive SubjectsHypertension: Journal of the American Heart Association, 43
-
A. Chobanian, G. Bakris, H. Black, W. Cushman, L. Green, J. Izzo, Daniel Jones, B. Materson, S. Oparil, J. Wright, E. Roccella (2003)
Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.Hypertension, 42 6
-
G. Viberti, N.M. Wheeldon (2002)
on behalf of the MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effectCirculation, 106
-
J.R. Sowers (2004)
Insulin resistance and hypertensionAm J Physiol Heart Circ Physiol, 286
-
J. Koster, M. Remedi, Ricard Masia, B. Patton, Ailing Tong, C. Nichols (2006)
Expression of ATP-Insensitive KATP Channels in Pancreatic β-Cells Underlies a Spectrum of Diabetic PhenotypesDiabetes, 55
-
L. Opie, H. Parving (2002)
Diabetic nephropathy: can renoprotection be extrapolated to cardiovascular protection?Circulation, 106 6
-
K. Ong, B. Cheung, Y. Man, C. Lau, K. Lam (2007)
Prevalence, Awareness, Treatment, and Control of Hypertension Among United States Adults 1999–2004Hypertension, 49
-
E. Ferrannini, G. Buzzigoli, R. Bonadonna, M. Giorico, M. Oleggini, L. Graziadei, R. Pedrinelli, L. Brandi, S. Bevilacqua (1987)
Insulin resistance in essential hypertension.The New England journal of medicine, 317 6
-
Malcolm Law, N. Wald, Joan Morris, Rachel Jordan (2003)
Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trialsBMJ : British Medical Journal, 326
-
A. Sachse, CN Verboom, B. Jäger (2002)
Efficacy of eprosartan in combination with HCTZ in patients with essential hypertensionJournal of Human Hypertension, 16
-
F. Turnbull, B. Neal, C. Algert, J. Chalmers, N. Chapman, J. Cutler, M. Woodward, S. MacMahon (2005)
Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials.Archives of internal medicine, 165 12
-
B. Palmer (2004)
Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system.The New England journal of medicine, 351 6
-
P. Ridker, E. Danielson, N. Rifai, R. Glynn (2006)
Valsartan, Blood Pressure Reduction, and C-Reactive Protein: Primary Report of the Val-MARC TrialHypertension, 48
-
J. Mason, H. Dickinson, D. Nicolson, F. Campbell, G. Ford, B. Williams (2005)
The diabetogenic potential of thiazide-type diuretic and beta-blocker combinations in patients with hypertensionJournal of Hypertension, 23
-
C. Mogensen (2005)
New concepts in blood pressure-lowering management in diabetic patients: the case for early ACE inhibitor combination therapy with diureticsJournal of Human Hypertension, 19
-
N. Brown, D. Vaughan (1998)
Angiotensin-converting enzyme inhibitors.Circulation, 97 14
-
J. Sowers (1990)
Insulin resistance and hypertensionMolecular and Cellular Endocrinology, 74
-
Hussam Abuissa, Philip Jones, S. Marso, J. O’Keefe (2005)
Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials.Journal of the American College of Cardiology, 46 5
-
P. Whelton, J. Barzilay, W. Cushman, B. Davis, Ekambaram Iiamathi, J. Kostis, F. Leenen, G. Louis, K. Margolis, D. Mathis, J. Moloo, C. Nwachuku, D. Panebianco, D. Parish, S. Pressel, D. Simmons, U. Thadani (2005)
Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).Archives of internal medicine, 165 12
-
B. Brenner, M. Cooper, D. Zeeuw, W. Keane, W. Mitch, H. Parving, G. Remuzzi, S. Snapinn, Zhonxin Zhang, S. Shahinfar (2001)
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.The New England journal of medicine, 345 12
-
Samy Suissa, T. Hutchinson, James Brophy, A. Kezouh (2006)
ACE-inhibitor use and the long-term risk of renal failure in diabetes.Kidney international, 69 5
-
D.S. Hanes, M.R. Weir (2005)
Hypertension -
H. Black, Barry Davis, J. Barzilay, C. Nwachuku, Charles Baimbridge, H. Marginean, J. Wright, J. Basile, N. Wong, P. Whelton, R. Dart, U. Thadani (2007)
Metabolic and Clinical Outcomes in Nondiabetic Individuals With the Metabolic Syndrome Assigned to Chlorthalidone, Amlodipine, or Lisinopril as Initial Treatment for HypertensionDiabetes Care, 31
-
D. Zeeuw, G. Remuzzi, H. Parving, W. Keane, Zhongxin Zhang, S. Shahinfar, S. Snapinn, M. Cooper, W. Mitch, B. Brenner (2004)
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.Kidney international, 65 6
-
F. Messerli, E. Grossman, G. Leonetti (2004)
Antihypertensive therapy and new onset diabetesJournal of Hypertension, 22
-
B. Neal (2001)
The Blood Pressure Lowering Treatment Trialists' Collaboration -
L. Fields, V. Burt, J. Cutler, Jeffrey Hughes, E. Roccella, P. Sorlie (2004)
The Burden of Adult Hypertension in the United States 1999 to 2000: A Rising TideHypertension, 44
-
V. Esnault, A. Ekhlas, C. Delcroix, M. Moutel, J. Nguyen (2005)
Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents.Journal of the American Society of Nephrology : JASN, 16 2
-
J. Mann, H. Gerstein, S. Yusuf (2000)
Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.The Lancet
-
S. Chrysant, M. Weber, Antonia Wang, D. Hinman (2004)
Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide.American journal of hypertension, 17 3
-
S. Julius, S. Kjeldsen, M. Weber, H. Brunner, S. Ekman, L. Hansson, T. Hua, J. Laragh, G. Mcinnes, Lada Mitchell, F. Plat, A. Schork, Beverly Smith, A. Zanchetti (2004)
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trialThe Lancet, 363
-
G. Reaven (1991)
Relationship Between Insulin Resistance and HypertensionDiabetes Care, 14
-
E. Lewis, L. Hunsicker, W. Clarke, T. Berl, M. Pohl, J. Lewis, E. Ritz, R. Atkins, R. Rohde, I. Raz (2001)
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.The New England journal of medicine, 345 12
-
B. Palmer (2007)
Proteinuria as a Therapeutic Target in Patients with Chronic Kidney DiseaseAmerican Journal of Nephrology, 27
-
C. Arauz-Pacheco, Marian Parrott, P. Raskin (2004)
Hypertension management in adults with diabetes.Diabetes care, 27 Suppl 1
-
W. Cushman, C. Ford, J. Cutler, K. Margolis, B. Davis, R. Grimm, H. Black, B. Hamilton, J. Holland, C. Nwachuku, V. Papademetriou, J. Probstfield, J. Wright, M. Alderman, R. Weiss, L. Piller, Judy Bettencourt, Sandra Walsh (2002)
Original Papers. Success and Predictors of Blood Pressure Control in Diverse North American Settings: The Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)The Journal of Clinical Hypertension, 4
-
W. Elliott (2000)
Therapeutic trials comparing angiotensin converting enzyme inhibitors and Angiotensin II receptor blockersCurrent Hypertension Reports, 2
-
E. Lewis, L. Hunsicker, R. Bain, R. Rohde (1993)
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.The New England journal of medicine, 329 20
-
S. Kjeldsen, I. Os, Aud Høieggea, K. Beckey, G. Gleim, S. Oparil (2005)
Fixed-Dose Combinations in the Management of HypertensionAmerican Journal of Cardiovascular Drugs, 5
-
J. Cutler (2006)
Thiazide-associated glucose abnormalities: prognosis, etiology, and prevention: is potassium balance the key?Hypertension, 48 2
-
H. Parving, Hendrik Lehnert, J. Bröchner-Mortensen, R. Gomis, S. Andersen, P. Arner (2001)
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.The New England journal of medicine, 345 12
-
T. Pollare, H. Lithell, C. Berne (1990)
Insulin resistance is a characteristic feature of primary hypertension independent of obesity.Metabolism: clinical and experimental, 39 2
-
(2000)
Healthy people 2010: understanding and improving health -
M. Burnier (2001)
Angiotensin II Type 1 Receptor BlockersCirculation: Journal of the American Heart Association, 103
-
P. Pablos-Velasco, F. Toral, Juan Esmatjes, F. Fernández-Vega, Martín Torre, A. Pozuelo, L. Ruilope (2002)
Losartan titration versus diuretic combination in type 2 diabetic patientsJournal of Hypertension, 20
-
E. Lewis, L. Hunsicker, R. Bain, R. Rohde (1993)
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy.The New England Journal of Medicine, 330
-
J. Pool, R. Glazer, M. Weinberger (2007)
Clin Ther -
B. Dahlöf, R. Devereux, S. Kjeldsen, S. Julius, G. Beevers, U. Faire, F. Fyhrquist, H. Ibsen, Krister Kristiansson, O. Lederballe‐Pedersen, L. Lindholm, M. Nieminen, P. Omvik, S. Oparil, H. Wedel (2002)
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololThe Lancet, 359
-
S.E. Kjeldsen, I. Os, A. Høieggen (2005)
Fixed-dose combinations in the management of hypertension: defining the place of angiotensin receptor antagonists and hydrochlorothiazideAm J Cardiovasc Drugs, 5
-
D. Hanes, M. Weir (2005)
Chapter 25 – Renal Protection in Chronic Kidney Disease -
J. Mallion, R. Carretta, P. Trenkwalder, JEAN-FELIPE Martinez, A. Tykarski, I. Teitelbaum, P. Oddou, T. Fagan (2003)
Valsartan/Hydrochlorothiazide is Effective in Hypertensive Patients Inadequately Controlled by Valsartan MonotherapyBlood Pressure, 12
-
N. Miller, M. Hill, T. Kottke, I. Ockene (1997)
The multilevel compliance challenge: recommendations for a call to action. A statement for healthcare professionals.Circulation, 95 4
-
G. Viberti, N. Wheeldon (2002)
Microalbuminuria Reduction With Valsartan in Patients With Type 2 Diabetes Mellitus: A Blood Pressure–Independent EffectCirculation: Journal of the American Heart Association, 106
-
A. Zillich, J. Garg, S. Basu, G. Bakris, B. Carter (2006)
Thiazide Diuretics, Potassium, and the Development of Diabetes: A Quantitative ReviewHypertension, 48
-
E. Ritz (2006)
Heart and kidney: fatal twins?The American journal of medicine, 119 5 Suppl 1
-
G. Mancia, G. Grassi, A. Zanchetti (2006)
New-onset diabetes and antihypertensive drugs.Journal of hypertension, 24 1
-
C. Salerno, L. Demopoulos, R. Mukherjee, A. Gradman (2004)
Combination Angiotensin Receptor Blocker/Hydrochlorothiazide as Initial Therapy in the Treatment of Patients With Severe HypertensionThe Journal of Clinical Hypertension, 6
-
Y. Lacourciére, L. Poirier (2003)
Antihypertensive effects of two fixed-dose combinations of losartan and hydrochlorothiazide versus hydrochlorothiazide monotherapy in subjects with ambulatory systolic hypertension.American journal of hypertension, 16 12
-
D. Sica (2005)
Pharmacotherapy Review: Angiotensin Receptor AntagonistsThe Journal of Clinical Hypertension, 7
-
J. Douglas, G. Bakris, M. Epstein, K. Ferdinand, C. Ferrario, J. Flack, K. Jamerson, Wendell Jones, J. Haywood, Randall Maxey, E. Ofili, E. Saunders, E. Schiffrin, D. Sica, J. Sowers, D. Vidt (2003)
Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks.Archives of internal medicine, 163 5
-
J. Pool, R. Glazer, M. Weinberger, R. Alvarado, Jie Huang, A. Graff (2007)
Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults.Clinical therapeutics, 29 1
-
J. Barzilay, J. Cutler, B. Davis (2007)
Antihypertensive medications and risk of diabetes mellitusCurrent Opinion in Nephrology and Hypertension, 16
-
A. Mimran, Matthew Weir (2005)
Angiotensin‐receptor blockers and diuretics—Advantages of combinationBlood Pressure, 14
-
Hope Investigators, B. Wolffenbuttel (2000)
Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudyThe Lancet, 355
-
L. Phillips, W. Branch, C. Cook (2001)
Clinical inertiaAnn Int Med, 135
-
Y. Lacourciére, L. Poirier, D. Hébert, Linda Assouline, Pelle Stolt, B. Réhel, Y. Khder (2005)
Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial.Clinical therapeutics, 27 7
-
H. Buter, M. Hemmelder, G. Navis, P. Jong, D. Zeeuw (1998)
The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 13 7
-
B. Palmer (2002)
Renal dysfunction complicating the treatment of hypertension.The New England journal of medicine, 347 16
- Publisher
- Springer Journals
- Copyright
- Copyright © 2008 by Adis Data Information BV
- Subject
- Medicine & Public Health; Cardiology; Pharmacotherapy; Pharmacology/Toxicology
- ISSN
- 1175-3277
- eISSN
- 1179-187X
- DOI
- 10.2165/00129784-200808010-00002
- pmid
- 18303933
- Publisher site
- See Article on Publisher Site
Abstract
Most hypertensive patients will require more than one antihypertensive drug to lower BP below target levels. The combination of diuretics with renin-angiotensin system (RAS) antagonists offers several advantages to include additive BP-lowering efficacy and enhanced reductions in urinary protein excretion. Thiazide diuretics are associated with metabolic complications that are particularly evident when used in high doses. When used in combination with RAS blockade, metabolic complications such as hypokalemia are minimized. The avoidance of hypokalemia has been linked to less thiazide-induced glucose intolerance. Patient persistence on therapy is dependent on well tolerated drug combinations.
Journal
American Journal of Cardiovascular Drugs – Springer Journals
Published: Sep 20, 2012